Delivery Order SPE2DR25D9331-SPE2DR26FQPU1
- Not listed
- The Defense Logistics Agency awarded a $79,430.86 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Perjeta 420 mg/14 mL vials. The award, issued on November 13, 2025, with an ultimate completion date of December 5, 2025, carries no set-aside designation and was issued without subcontractor involvement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite...
- The Defense Logistics Agency awarded a $77,830.30 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. The delivery order was issued on October 20, 2025, with an ultimate completion date of November 10, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This...
- The Defense Logistics Agency awarded a $41,441.33 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. This firm fixed-price delivery order, issued on November 7, 2025, with an ultimate completion date of December 2, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The...
- The Defense Logistics Agency awarded a delivery order valued at $91,145.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 ml vials. This firm fixed-price delivery order, issued on August 12, 2025, with an ultimate completion date of September 3, 2025, represents a targeted pharmaceutical procurement to support Department of Defense healthcare operations. The award carries no set-aside...
- The Defense Logistics Agency awarded a $27,343.62 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The contract, issued on May 6, 2025, with an ultimate completion date of May 28, 2025, represents a focused procurement action without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $31,900.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 420 mg/14 mL vials of Perjeta, an oncology treatment medication. The award was issued on September 8, 2025, with an ultimate completion date of September 29, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The contract, valued at $9,114.54 with a firm fixed-price structure, was awarded on September 23, 2025, with an ultimate completion date of October 15, 2025. This delivery order was issued without a set-aside designation, leveraging the vendor's competitive standing as a...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc. on September 22, 2025, for the supply of Perjeta 420 mg/14 mL vials totaling $27,343.62 with firm fixed pricing. This delivery order was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA valued at $499,999,999 and effective through November 2026. The award carries no set-aside designation and requires completion by October 14, 2025, with performance based in Park Ridge,...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,229.08 to DMS Pharmaceutical Group Inc. for the supply of Perjeta (pertuzumab) 420 mg/14 mL vials. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its Park Ridge facility with an ultimate completion date of October 10, 2025. The award was issued on September 19, 2025, without a set-aside designation, allowing...
- The Defense Logistics Agency (DLA) issued a delivery order valued at $36,458.16 to DMS Pharmaceutical Group Inc. on September 17, 2025, for the supply of Perjeta (pertuzumab) 420 mg/14 mL vials. This firm fixed-price delivery order is expected to be completed by October 8, 2025, with fulfillment to occur at the contractor's location in Park Ridge, Illinois. The award was made without set-aside designation, and DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler,...
- SPE2DR25D9331Indefinite Delivery Contract
- SPE2DR25D9331-SPE2DR26FQPU1Delivery Order
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $46,509.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The award was issued on November 13, 2025, with an ultimate completion date of December 5, 2025, and carries no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with a $499.9 billion ceiling value under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was also awarded on November 13, 2025, and extends through December 31, 2036. The PPV-G GEN V contract represents part of the broader $30.3 billion Defense Logistics Agency pharmaceutical acquisition strategy and authorizes the issuance of firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription medications, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group's extensive product portfolio encompasses oncology treatments, immunosuppressants, specialty pharmaceuticals, vaccines, and routine medications, positioning the company as a critical supplier within the federal military medical supply chain. No subcontractor relationships were identified in the award documentation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $46.5k | 11/13/25 |